ArticleMedical oncology (Northwood, London, England)2025
Nanoemulsion encapsulation enhanced the anti-tumor potency of pomegranate polysaccharides by suppressing oxidative stress, inflammation, and tumor metastasis induced by 1,2-dimethylhydrazine in rats.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) treatment has progressed, but more effective therapeutic targets are still needed. Pomegranate polysaccharides (PGPs) show promising anti-tumor activity but have limited bioavailability. Their stability and delivery can be improved using nanostructured systems, such as nanoemulsions (NEs). This study investigated the chemopreventive effect of PGPs and their nanoemulsion (PGPs-NE) against 1,2-dimethylhydrazine (DMH)-induced CRC in rats. Male Wistar rats received subcutaneous DMH injections (20 mg/kg) and were orally administered PGPs and PGPs-NE at 200 mg/kg body weight for 12 weeks. CRC progression was assessed by measuring tumor burden, mucosal plaque lesions, aberrant crypt foci (ACF), cecal short-chain fatty acids (SCFAs), oxidative stress markers, liver enzymes, inflammatory cytokine (IL-6), matrix metalloproteinase-9 (MMP-9), DNA fragmentation, histological changes, and PCNA expression. DMH significantly decreased antioxidant enzyme activities and SCFA levels while increasing tumor growth, inflammation, DNA damage, and cell proliferation. Both PGPs and PGPs-NE markedly improved these parameters, with PGPs-NE showing greater effectiveness in reducing tumor weight, restoring antioxidant levels, and inhibiting the expression of PCNA, MMP-9, and IL-6. Furthermore, PGPs-NE elevated SCFA levels and promoted goblet cell differentiation, indicating modulation of the microbiota. Molecular docking confirmed strong binding of pectin, the main component of PGPs, with key CRC-related kinases CDK1 and CDK2, suggesting interference with cell cycle regulation. These findings support PGPs-NE as a promising nano-formulated therapy for CRC prevention, targeting oxidative stress, inflammation, metastasis, and proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.